retatrutide status fda Before Approval: What Nurses Need to Know Buy Peptide Sciences Retatrutide 20mg

Soliqua 100/33 (insulin glargine and lixisenatide injection) [package insert]

Authors: John Knight is associate professor

Regulatory Frameworks and Supply Dynamics: In December 2025, the FDA approved the first oral GLP-1 for weight loss-Novo Nordisk's once-daily semaglutide pill, which launched in January 2026, significantly expanding accessibility for patients averse to injections [3]

Reported side effects are similar to other GLP-1 type drugs mainly mild to moderate gastrointestinal symptoms like nausea or diarrhea, especially during dose escalation

Trimethylaminuria may be primary or secondary: One study suggests between 1 in 200,000 and 1 in 1 million people worldwide have trimethylaminuria